S&P 500   4,286.74 (+0.45%)
DOW   33,815.08 (+0.45%)
QQQ   352.16 (+0.96%)
AAPL   179.76 (+1.09%)
MSFT   324.61 (+0.38%)
META   266.76 (+1.20%)
GOOGL   122.36 (-0.11%)
AMZN   124.30 (+2.53%)
TSLA   231.20 (+2.95%)
NVDA   385.06 (+2.75%)
NIO   7.65 (-1.42%)
BABA   86.60 (+1.55%)
AMD   121.05 (+2.73%)
T   15.94 (-0.99%)
F   13.56 (-0.22%)
MU   65.17 (-2.82%)
CGC   0.70 (-2.89%)
GE   106.92 (+0.79%)
DIS   92.47 (-0.05%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.21 (+0.27%)
NFLX   404.20 (+1.11%)
S&P 500   4,286.74 (+0.45%)
DOW   33,815.08 (+0.45%)
QQQ   352.16 (+0.96%)
AAPL   179.76 (+1.09%)
MSFT   324.61 (+0.38%)
META   266.76 (+1.20%)
GOOGL   122.36 (-0.11%)
AMZN   124.30 (+2.53%)
TSLA   231.20 (+2.95%)
NVDA   385.06 (+2.75%)
NIO   7.65 (-1.42%)
BABA   86.60 (+1.55%)
AMD   121.05 (+2.73%)
T   15.94 (-0.99%)
F   13.56 (-0.22%)
MU   65.17 (-2.82%)
CGC   0.70 (-2.89%)
GE   106.92 (+0.79%)
DIS   92.47 (-0.05%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.21 (+0.27%)
NFLX   404.20 (+1.11%)
S&P 500   4,286.74 (+0.45%)
DOW   33,815.08 (+0.45%)
QQQ   352.16 (+0.96%)
AAPL   179.76 (+1.09%)
MSFT   324.61 (+0.38%)
META   266.76 (+1.20%)
GOOGL   122.36 (-0.11%)
AMZN   124.30 (+2.53%)
TSLA   231.20 (+2.95%)
NVDA   385.06 (+2.75%)
NIO   7.65 (-1.42%)
BABA   86.60 (+1.55%)
AMD   121.05 (+2.73%)
T   15.94 (-0.99%)
F   13.56 (-0.22%)
MU   65.17 (-2.82%)
CGC   0.70 (-2.89%)
GE   106.92 (+0.79%)
DIS   92.47 (-0.05%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.21 (+0.27%)
NFLX   404.20 (+1.11%)
S&P 500   4,286.74 (+0.45%)
DOW   33,815.08 (+0.45%)
QQQ   352.16 (+0.96%)
AAPL   179.76 (+1.09%)
MSFT   324.61 (+0.38%)
META   266.76 (+1.20%)
GOOGL   122.36 (-0.11%)
AMZN   124.30 (+2.53%)
TSLA   231.20 (+2.95%)
NVDA   385.06 (+2.75%)
NIO   7.65 (-1.42%)
BABA   86.60 (+1.55%)
AMD   121.05 (+2.73%)
T   15.94 (-0.99%)
F   13.56 (-0.22%)
MU   65.17 (-2.82%)
CGC   0.70 (-2.89%)
GE   106.92 (+0.79%)
DIS   92.47 (-0.05%)
AMC   4.61 (-2.54%)
PFE   39.13 (+0.62%)
PYPL   64.21 (+0.27%)
NFLX   404.20 (+1.11%)
NASDAQ:SWAV

Shockwave Medical (SWAV) Stock Forecast, Price & News

$288.18
+0.93 (+0.32%)
(As of 01:09 PM ET)
Compare
Today's Range
$285.20
$290.45
50-Day Range
$214.16
$302.68
52-Week Range
$154.45
$320.54
Volume
112,907 shs
Average Volume
537,618 shs
Market Capitalization
$10.55 billion
P/E Ratio
45.45
Dividend Yield
N/A
Price Target
$273.78

Shockwave Medical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
5.1% Downside
$273.78 Price Target
Short Interest
Healthy
3.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.80mentions of Shockwave Medical in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$7.12 M Sold Last Quarter
Proj. Earnings Growth
25.44%
From $3.97 to $4.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

153rd out of 981 stocks

Surgical & Medical Instruments Industry

16th out of 99 stocks


SWAV stock logo

About Shockwave Medical (NASDAQ:SWAV) Stock

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Receive SWAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shockwave Medical and its competitors with MarketBeat's FREE daily newsletter.

SWAV Stock News Headlines

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market (SWAV)
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
Shockwave Medical, Fast Grower, In Boston Scientific's Sights?
Shockwave earnings are growing at triple-digit rates. The company easily beat Q1 views. Boston Scientific is reportedly interested in acquiring Shockwave.
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Are Small Caps a Harbinger of Market Declines? (SWAV)
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action.
Shockwave Medical (NASDAQ: SWAV)
The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Shockwave Medical Publishes 2022 ESG Report
See More Headlines

SWAV Price History

SWAV Company Calendar

Last Earnings
5/08/2023
Today
6/08/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SWAV
Fax
N/A
Employees
1,001
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$273.78
High Stock Price Forecast
$325.00
Low Stock Price Forecast
$165.00
Forecasted Upside/Downside
-4.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$216 million
Pretax Margin
26.36%

Debt

Sales & Book Value

Annual Sales
$489.73 million
Cash Flow
$6.06 per share
Book Value
$14.15 per share

Miscellaneous

Free Float
35,356,000
Market Cap
$10.51 billion
Optionable
Not Optionable
Beta
1.00

Key Executives

  • Douglas Evan GodshallDouglas Evan Godshall
    President, Chief Executive Officer & Director
  • Mike Maszy
    Senior Vice President-Operations
  • Daniel Puckett
    Chief Financial Officer
  • Beaux Alexander
    Vice President-Clinical Affairs
  • W. Patrick Stephens
    Vice President-Research & Development













SWAV Stock - Frequently Asked Questions

Should I buy or sell Shockwave Medical stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings
or view top-rated stocks.

What is Shockwave Medical's stock price forecast for 2023?

9 equities research analysts have issued 1-year price targets for Shockwave Medical's stock. Their SWAV share price forecasts range from $165.00 to $325.00. On average, they anticipate the company's stock price to reach $273.78 in the next year. This suggests that the stock has a possible downside of 4.7%.
View analysts price targets for SWAV
or view top-rated stocks among Wall Street analysts.

How have SWAV shares performed in 2023?

Shockwave Medical's stock was trading at $205.61 at the beginning of 2023. Since then, SWAV stock has increased by 39.7% and is now trading at $287.25.
View the best growth stocks for 2023 here
.

When is Shockwave Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SWAV earnings forecast
.

How were Shockwave Medical's earnings last quarter?

Shockwave Medical, Inc. (NASDAQ:SWAV) released its quarterly earnings data on Monday, May, 8th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.22. The business earned $161.10 million during the quarter, compared to analyst estimates of $147.30 million. Shockwave Medical had a trailing twelve-month return on equity of 55.22% and a net margin of 43.18%. The business's quarterly revenue was up 72.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.39 EPS.

What guidance has Shockwave Medical issued on next quarter's earnings?

Shockwave Medical issued an update on its FY 2023 earnings guidance on Monday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $700.00 million-$720.00 million, compared to the consensus revenue estimate of $671.58 million.

What is Doug Godshall's approval rating as Shockwave Medical's CEO?

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Shockwave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

When did Shockwave Medical IPO?

(SWAV) raised $75 million in an initial public offering on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Shockwave Medical's stock symbol?

Shockwave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Who are Shockwave Medical's major shareholders?

Shockwave Medical's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (12.38%), FMR LLC (7.16%), Price T Rowe Associates Inc. MD (3.82%), JPMorgan Chase & Co. (3.48%), State Street Corp (3.30%) and Artisan Partners Limited Partnership (2.90%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy, Sofinnova Capital Vii Fcpr and Trinh Phung.
View institutional ownership trends
.

How do I buy shares of Shockwave Medical?

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Shockwave Medical's stock price today?

One share of SWAV stock can currently be purchased for approximately $287.25.

How much money does Shockwave Medical make?

Shockwave Medical (NASDAQ:SWAV) has a market capitalization of $10.51 billion and generates $489.73 million in revenue each year. The company earns $216 million in net income (profit) each year or $6.34 on an earnings per share basis.

How many employees does Shockwave Medical have?

The company employs 1,001 workers across the globe.

How can I contact Shockwave Medical?

Shockwave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (877) 775-4846 or via email at investors@shockwavemedical.com.

This page (NASDAQ:SWAV) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -